Cat. No. | Product name | CAS No. |
DC8054 |
Cariprazine (RGH-188)
Featured
Cariprazine (RGH-188) is a novel putative antipsychotic drug that exerts partial agonism at dopamine D2/D3 receptors, with preferential binding to D3 receptors, and partial agonism at serotonin 5-HT1A receptors. |
839712-12-8 |
DC9012 |
Carisoprodol
Carisoprodol is a centrally acting skeletal muscle relaxant of the carbamate class and produces all the effects associated with barbiturate receptor ligands. |
78-44-4 |
DC21875 |
CARM1 inhibitor 9
CARM1 inhibitor 9 is a potent, selective inhibitor of arginine methyltransferase 1 (CARM1, PRMT4) with IC50 of 94 nM. |
2180931-09-1 |
DC24110 |
CARM1-IN-1
Featured
CARM1-IN-7g is a potent, selective coactivator-associated arginine methyltransferase 1 (CARM1) with IC50 of 8.6 uM, exhibits lower or no activity against a panel of different PRMTs or HKMTs (>80-fold over PRMT1 and SET7). |
1020399-49-8 |
DC8972 |
Carmustine
Featured
Carmustine is a cell-cycle phase nonspecific alkylating antineoplastic agent. |
154-93-8 |
DC20119 |
Carnostatine (SAN9812)
Carnostatine (SAN9812) is a specific and highly selective carnosinase (CN1) inhibitor with a Ki of 11 nM. |
|
DC11354 |
Carteolol (hydrochloride)
Carteolol is an antagonist of β-adrenergic receptors (Kd = 13 nM). |
51781-21-6 |
DC8113 |
Carubicin
Featured
Carubicin is an anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. |
50935-04-1 |
DC9119 |
Carvedilol
Carvedilol(BM14190) is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation. |
72956-09-3 |
DC10539 |
POL1 inhibitor(POL1-IN-1)
Featured
CAS 1822358-25-7 |
1822358-25-7 |
DC11250 |
Casein Kinase inhibitor A51
Featured
Casein Kinase inhibitor A51 (CKIα inhibitor A51) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=0.5-20 nM, CKIα Kd=5.3 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19; target both CDK7 and CDK9 with low nM Kd values; induces leukemia cell apoptosis at <160 nM, in correlation to the capacity to stabilize p53; shows high and selective sensitivity against leukemic CFUs in colony-forming unit (CFU) assay, without effect on normal hematopoietic CFUs; blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, induce apoptosis, abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1; demonstrates therapeutic efficacy with preserved hematopoiesis and leukemia cure potential in AML mouse models. |
2079068-74-7 |
DC11251 |
Casein Kinase inhibitor A86
Casein Kinase inhibitor A86 (CKIα inhibitor A86) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=1-10 nM, CKIα Kd=9.8 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19. |
2079069-01-3 |
DC8013 |
CASIN
Featured
CASIN is a Cdc42 GTPase inhibitor (IC50 = 2 μM). |
425399-05-9 |
DC22402 |
Casopitant
Casopitant (GW679769) is a potent, centrally-acting neurokinin 1 (NK1) receptor antagonist (pKi=9.48) with antidepressant and antiemetic activities. |
414910-27-3 |
DC22403 |
Casopitant mesylate
Featured
Casopitant (GW679769) is a potent, centrally-acting neurokinin 1 (NK1) receptor antagonist (pKi=9.48) with antidepressant and antiemetic activities. |
414910-30-8 |
DCAPI1497 |
Cancidas
Featured
Caspofungin is a semi-synthetic analogue of pneumocandin B0 with improved water solubility, a significant limitation in the development of the echinocandin class as pharmaceuticals. Caspofungin acts by inhibition of the synthesis of β (1,3)-D-glucan, an e |
179463-17-3 |
DC22047 |
CAT639
CAT639 is an improved analog of ATV399 that exhibits improved β-cell viability and insulin secretion in the rat insulin-producing INS1E cells and primary rat dispersed islet cells, inhibits dimerization of iNOS. |
|
DCAPI1130 |
Catharanthine
Catharanthine inhibits nicotinic receptor mediated diaphragm contractions with IC50 of 59.6 µM. |
2468-21-5 |
DC22206 |
Cathepsin B inhibitor RC1
Cathepsin B inhibitor RC1 is a small-molecule that blocks the process of anthrax lethal toxin (LT) cytotoxicity, inhibits enzymatic activity of host cathepsin B that mediates the escape of toxins into the cytoplasm from late endosomes. |
775573-79-0 |
DCAPI1119 |
Cathepsin Inhibitor 1
Featured
Cathepsin Inhibitor 1 is an inhibitor of Cathepsin (L, L2, S, K, B) with pIC50 of 7.9, 6.7, 6.0, 5.5 and 5.2, respectively. |
225120-65-0 |
DC8482 |
CAY10415(MSDC-0160)
Featured
CAY10415 is a potent, antidiabetic drug of the TZD structural class. |
146062-49-9 |
DC10847 |
CAY10441(RO1138452)
Featured
CAY10441 is a Selective prostacyclin IP receptor antagonist. |
221529-58-4 |
DC10903 |
CAY10465
Featured
CAY10465 is an analog of resveratrol acting as a potent and selective aryl hydrocarbon receptor agonist, with a Ki of 0.2 nM. |
688348-33-6 |
DC10516 |
LW6(CAY10585)
Featured
CAY10585 prevented HIF-1 transcriptional activity with IC50 values of 2.6 and 0.7 µM, respectively. |
934593-90-5 |
DC12099 |
CAY10595
CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM. |
916047-16-0 |
DC10579 |
CAY 10602
Featured
CAY10602 is a SIRT1 activator. |
374922-43-7 |
DC8036 |
CAY10603
Featured
CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respectively. |
1045792-66-2 |
DC7738 |
CAY10683(Santacruzamate A)
Featured
CAY10683 is a potent and selective HDAC inhibitor with IC50 of 119 pM for HDAC2, >3600-fold selectivity over other HDACs. |
1477949-42-0 |
DC20607 |
Cazpaullone
Cazpaullone (9-Cyano-1-azapaullone) is a derivative of 1-Azakenpaullone, a potent, selective GSK3β inhibitor with IC50 of 8 nM, weakly inhibits CDK1/cyclin B and CDK5/p25 (IC50=0.5 and 0.3 uM). |
914088-64-5 |
DC4160 |
CB-03-01
Featured
CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use. |
19608-29-8 |
DC11709 |
CB-1158
CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM. |
2095732-06-0 |
DC8840 |
CB-5083
Featured
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . |
1542705-92-9 |
DC22986 |
CB5305630
CB5305630 is a potent and noncompetitive IRE1 RNase inhibitor with IC50 of 60 nM in the FRET-derepression assay. |
342388-50-5 |
DC20861 |
CB-618
CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates. |
1463520-70-8 |
DC20862 |
CB-618 sodium salt
CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates. |
1628207-16-8 |
DC20052 |
CB-6644
Featured
CB-6644 is a selective inhibitor of RUVBL1/2 complex with anti-cancer activity. CB-6644 blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. |
2316817-88-4 |
DC20863 |
CB-6673567
CB-6673567 is a potent, selective Adenylyl Cyclase 1 (AC1) inhibitor with IC50 of 77 uM, displays a 2- to 4-fold isoform selectivity over AC6. |
379218-90-3 |
DC10449 |
CB7921220
Featured
CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6). |
115453-99-1 |
DC8042 |
CB-839(Telaglenastat)
Featured
CB-839 is a potent, selective, reversible and orally bioavailable inhibitor of human glutaminase. |
1439399-58-2 |
DC10944 |
CBB3001
CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM. |
1639358-50-1 |
DC12623 |
CBK289001
CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM.. |
1212663-24-5 |
DC10617 |
CBL0137
Featured
CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. |
1197996-80-7 |
DC8377 |
CC-115
Featured
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. |
1228013-15-7 |
DC10146 |
CC-122(Avadomide)
Featured
CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. |
1015474-32-4 |
DC8497 |
CC-223
Featured
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM). |
1228013-30-6 |
DC7096 |
CC-401
Featured
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
1438391-30-0 |
DC20866 |
CC-671
Featured
CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively. |
1618658-88-0 |
DC12532 |
CC-90003
CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel. |
1621999-82-3 |
DC12590 |
CCB 02
Featured
CCB02 (CCB 02) is a specific small molecule inhibitor of CPAP-tubulin interaction with IC50 of 0.689 uM in AlphaScreen assay, selectively binds at the CPAP binding site of tubulin. |
2100864-57-9 |
DC23540 |
CCC07-01
CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays. |
2215102-35-3 |
DC7319 |
CCDC(TGR5-Receptor-Agonist)
Featured
CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8). |
1197300-24-5 |
DC9757 |
CCF642
Featured
CCF642 is a novel protein disulfide isomerases (PDI) inhibitor. |
346640-08-2 |
DC20867 |
CCG 102487
CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth. |
353787-50-5 |
DC20871 |
CCG 2979
CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor. |
328070-87-7 |
DC7979 |
CCG1423
Featured
CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. |
285986-88-1 |
DC10535 |
CCG-203971
Featured
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. |
1443437-74-8 |
DC11302 |
CCG215022
Featured
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively. |
1813527-81-9 |
DC10977 |
CCG-222740
CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay. |
1922098-69-8 |
DC20869 |
CCG-232601
CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF. |
1922099-21-5 |
DC22819 |
CCG-50014
Featured
CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test. |
883050-24-6 |
DC9612 |
CCG-63802
CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4. |
620112-78-9 |
DC9613 |
CCG-63808
CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. |
620113-73-7 |
DC22050 |
CCI-006
CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. |
292053-42-0 |
DC22049 |
CCI-007
CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485. |
939228-52-1 |
DC26030 |
CCMI
Featured
CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR). |
917837-54-8 |
DC12639 |
CCR1 inhibitor 19e
CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.. |
1220026-26-5 |
DC23528 |
CCR10 antagonist 1
CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM. |
1191031-97-6 |
DC12177 |
CCR2 antagonist 1
CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. |
1683534-96-4 |
DC12302 |
CCR2 antagonist 3
Featured
CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist. |
1380100-86-6 |
DC11204 |
CCR6 inhibitor 35
CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6). |
|
DC20876 |
CCT 068127
CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
660822-23-1 |
DC8776 |
CCT 137690
CCT 137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively). |
1095382-05-0 |
DC20875 |
CCT 365623 hydrochloride
CCT 365623 (CCT365623) hydrochloride is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
2126136-98-7 |
DC20874 |
CCT 365623
CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
2126134-01-6 |
DC7803 |
CCT007093
Featured
CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM. |
176957-55-4 |
DC22464 |
CCT-018159
CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM. |
171009-07-7 |
DC12283 |
CCT020312
CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK). |
324759-76-4 |
DC20872 |
CCT-031374
CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM. |
442535-46-8 |
DC23168 |
CCT128930
CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA. |
885499-61-6 |
DC23163 |
CCT129202
Featured
CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively. |
942947-93-5 |
DC10005 |
CCT196969
Featured
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. |
1163719-56-9 |
DC23828 |
CCT241161
CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively).. |
1163719-91-2 |
DC9399 |
CCT241533 (hydrochloride)
CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM. |
1431697-96-9 |
DC10911 |
CCT241736
Featured
CCT241736 is a novel, orally bioavailable Dual FLT3-Aurora Kinase Inhibitor. |
1402709-93-6 |
DC8324 |
CCT244747
Featured
CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies. |
1404095-34-6 |
DC10498 |
CCT251236
Featured
CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction. |
1693731-40-6 |
DC9968 |
CCT251545
Featured
CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM. |
1661839-45-7 |
DC9969 |
CCT251921
CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). |
1607837-31-9 |
DC10206 |
CCX140
CCX140 is a potent CCR2 antagonist. |
1100318-47-5 |
DC12549 |
CCX-354
CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA).. |
1010073-75-2 |
DC10955 |
CD12681
CD12681 (CD-12681) is a potent, selective RORγ inverse agonist with IC50 of 19 nM, displays no activity against a panel of nuclear receptors (RORα, RARγ, LXRβ, PPARγ and VDR). |
1952239-59-6 |
DC20332 |
CD38 inhibitor 78c
Featured
CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38. |
1700637-55-3 |
DC10491 |
CD437
Featured
CD437 is a synthetic retinoid that is an RARγ-selective agonist. It displays RARγ-dependent and -independent effects on differentiation and apoptosis. |
125316-60-1 |
DC20877 |
S8
Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM. |
1227475-09-3 |
DC10909 |
BN82002
Featured
CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties. |
396073-89-5 |
DC21877 |
Cdc7 inhibitor
Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.. |
2206698-92-0 |
DC10433 |
CDD3505
CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
173865-33-3 |
DC10432 |
CDD3506
CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
197913-15-8 |
DC22051 |
CDD-450
CDD-450 is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 while sparing p38α activation of PRAK and ATF2. |
|
DC8361 |
CDDO(Bardoxolone; RTA 401)
Featured
CDDO is a synthetic oleanane triterpenoid that blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2 in INF-γ-activated mouse macrophages with an IC50 value of 0.4 nM. |
218600-44-3 |
DC12026 |
CDDO-2P-Imidazolide
Featured
CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid. |
1883650-96-1 |
DC12027 |
CDDO-3P-Imidazolide
Featured
CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid. |
1883650-95-0 |
DC12025 |
CDDO imidazolide
Featured
CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities. |
443104-02-7 |
DC9277 |
C-DIM12
Featured
C-DIM12 is a novel synthetic activator of Nurr1. |
178946-89-9 |
DC10792 |
DIM-C-pPhOCH3(C-DIM5)
Featured
C-DIM5 is a Nur77 agonist. Activation of the orphan nuclear receptor Nur77 by C-DIM5 is associated with decreased cancer cell survival, |
33985-68-1 |
DC11158 |
CDK12 inhibitor 2
CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9. |
|
DC11872 |
CDK12 inhibitor E9 S-isomer
CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
2020052-55-3 |
DC20334 |
CDK2 inhibitor 73
Featured
CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM).. |
2079895-42-2 |
DC8596 |
Cdk4/6 Inhibitor IV
Cdk4/6 Inhibitor IV is a cell-permeable triaminopyrimidine compound acting as a reversible and ATP-competitive inhibitor of Cdk4/6 (IC50 = 1.5 µM and 5.6 µM for Cdk4/D1 and Cdk6/D1, respectively) |
359886-84-3 |
DC20921 |
CDK5 inhibitor 20-223
CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9. |
865317-30-2 |
DC12528 |
CDK9 inhibitor HH1
Featured
CDK9 inhibitor HH1 is a novel potent, highly selective CDK9 inhibitor.. |
204188-41-0 |
DC20335 |
CDK9-IN-8
Featured
CDK9-IN-8 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition. |
2105956-51-0 |
DC9478 |
CDK9-IN-1
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection. |
1415559-43-1 |
DC23138 |
CDK-I73
Featured
CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM, shows cytotoxicity against a broad CLL samples with mean LD50 of 80 nM. |
1421693-22-2 |
DC9390 |
CDK-IN-2
Featured
CDK-IN-2 is a potent and sepecific CDK inhibitor. |
1269815-17-9 |
DC11393 |
CDM-NAG
Featured
CDM-NAG is a useful tool compound to deliver the siRNA. |
1299292-01-5 |
DC10948 |
CDN1163
Featured
CDN1163 (CDN-1163) is a small molecule, allosteric activator of SERCA2, dose-dependently increases the Vmax of SERCA2 Ca2+-ATPase activity in ER microsomes; increases Ca2+-ATPase activity and significantly enhances Ca2+ uptake into the ER, attenuates H2O2-stimulated cell death in HEK cells; improves glucose homeostasis and metabolic parameters, increases glucose tolerance in ob/ob mice; CDN1163 reduces lipid accumulation and decreases lipogenesis in obese mice livers. |
892711-75-0 |
DC20879 |
CDP-840
CDP-840 (CDP840. |
162542-90-7 |
DC20880 |
CDP-840 hydrochloride
CDP-840 (CDP840. |
|
DC23463 |
CDPPB
Featured
CDPPB is a potent, selective, brain penetrant positive allosteric modulator of mGlu5 receptor with EC50 of 10 nM and 20 nM for human and rat mGluR5, respectively. |
781652-57-1 |
DC22446 |
CE-224535
CE-224535 (PF-04905428) is a potent and selective P2X7 receptor antagonist with IC50 of 1.4 nM (inhibition of the release of lL-1b from monocytes stimulated by ATP). |
724424-43-5 |
DC20881 |
CE-245677
CE-245677 is a potent, selective, orally active, dual Tie2/Trk kinase inhibitor with IC50 of 4.7 nM, 1 nM for Tie2 and TrkA/B, respectively. |
717899-97-3 |
DC20336 |
CE3F4
Featured
CE3F4 is a potent, noncompetitive EPAC1 inhibitor that blocks EPAC1-induced Rap1 activation both in cell-free systems and in intact cells and did not influence protein kinase A holoenzyme activity. |
143703-25-7 |
DC23912 |
Cecropin B
Cecropin B is an antimicrobial peptide with MICs(0.5 to 16 ug/ml) against Gramnegative strains. |
80451-05-4 |
DC20987 |
Cedazuridine
Featured
Cedazuridine (E7727) is a novel cytidine deaminase inhibitor, and a componet of ASTX727 for treatment of hematologic malignancies.. |
1141397-80-9 |
DC3170 |
Cediranib
Featured
Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
288383-20-0 |
DCAPI1386 |
Cefdinir (Omnicef)
Cefdinir (Omnicef) |
91832-40-5 |
DCAPI1024 |
Cefditoren pivoxil
Cefditoren pivoxil |
117467-28-4 |
DC8686 |
Cefetamet pivoxil hydrochloride
Cefetamet pivoxil hydrochloride is an oral third generation cephalosporin antibiotic. |
111696-23-2 |
DC9358 |
Cefmenoxime (hydrochloride)
Cefmenoxime hydrochloride is a third-generation cephalosporin antibiotic. |
75738-58-8 |
DCAPI1038 |
Cefoselis sulfate
Cefoselis sulfate |
122841-12-7 |
DC20190 |
Cefoxitin
Cefoxitin is a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. |
35607-66-0 |
DC8067 |
Cefozopran
Featured
Cefozopran (SCE-2787) is a new parenteral cephalosporin, against experimental infections in mice. |
113359-04-9 |
DC9356 |
Cefpiramide (sodium)
Cefpiramide sodium (SM-1652; Wy-44635) is a new Pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity. |
74849-93-7 |
DC8687 |
Cefpirome sulfate
Cefpirome Sulfate is a fourth generation cephalosporin antibiotic. |
98753-19-6 |
DCAPI1033 |
Cefprozil hydrate (Cefzil)
Cefprozil hydrate (Cefzil) |
121123-17-9 |
DC9355 |
Ceftibuten (dihydrate)
Ceftibuten dihydrate is a third-generation cephalosporin antibiotic. |
118081-34-8 |
DC12245 |
Ceftizoxime
Ceftizoxime is a bacterial inhibitor which acts by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan. |
68401-81-0 |
DCAPI1155 |
Celastrol
Featured
Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. |
34157-83-0 |
DCAPI1491 |
Celecoxib
Featured
Celecoxib is a selective Cox-2 inhibitor (IC50 of 40 nM). Celecoxib shows low sensitivity against Cox-1 (IC50 of 15 μM). Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 (IC50of 32.86 μM) and CNE1-LM |
169590-42-5 |
DC7569 |
Z-LEHD-FMK
Cell permeable fluoromethyl ketone (FMK)-derivatized peptides act as effective irreversible Caspase inhibitors with no cytotoxic effects and, therefore, are useful tools for studying Caspase activity. |
210345-04-3 |
DC7568 |
Z-DEVD-FMK
Featured
Cell-permeable, irreversible inhibitor of caspase-3/CPP32; inhibits tumor cell apoptosis. Neuroprotective in rat hippocampus following seizures in vivo. |
210344-95-9 |
DC9923 |
CeMMEC1
Featured
CeMMEC1 is a novel potent inhibitor of the second bromodomain of TAF1, binding neither the first nor the second bromodomain of BRD4. |
440662-09-9 |
DC23359 |
CeMMEC2
CeMMEC2 is a novel potent BRD4 inhibitor with IC50 of 0.9 uM, binds to both bromodomains of BRD4, comparably to (S)-JQ1.. |
902955-25-3 |
DC10357 |
Cenerimod
Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM. |
1262414-04-9 |
DC10316 |
Cenicriviroc
Featured
Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity. |
497223-25-3 |
DC21554 |
AS 703569
Cenisertib (AS 703569;R763) is a novel potent, orally available inhibitor of Aurora kinases, exhibits signifficant anti-proliferative activity against a wide range of tumor cells both in vitro and in vivo (A549 EC50=9 nM). |
871357-89-0 |
DC12318 |
Centanafadine hydrochloride (EB-1020 (hydrochloride))
Centanafadine (hydrochloride) is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively. |
923981-14-0 |
DC12319 |
Centanafadine (EB-1020)
Centanafadine is dual norepinephrine (NE)/dopamine (DA) transporter inhibitor, also inhibits serotonin transporter, with IC50s of 6 nM, 38 nM and 83 nM for human NE, DA and serotonin transporter , respectively. |
924012-43-1 |
DC10011 |
Centrinone-B
Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM). |
1798871-31-4 |
DC22796 |
CEP-1347
CEP-1347 (KT-7515) is a potent and selective MLK inhibitor that completely rescues motoneurons and inhibits JNK1 activation with IC50 of 20 nM. |
156177-65-0 |
DC8138 |
CEP-28122
Featured
CEP-28122 is a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. |
1022958-60-6 |
DC8777 |
CEP-32496 hydrochloride
CEP-32496 Hcl is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. |
1227678-26-3 |
DC8196 |
CEP-32496
Featured
CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. |
1188910-76-0 |
DC7099 |
CEP33779
Featured
CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells. |
1257704-57-6 |
DC8009 |
CEP-37440
Featured
CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma). |
1391712-60-9 |
DC10337 |
CEP-40783
Featured
CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively. |
1437321-24-8 |
DC23856 |
CEP-7055
CEP-7055 is a potent, orally active, pan inhibitor of VEGFR, CEP-7055 is the dimethylglycine ester prodrug of CEP-5214, which inhibits human VEGFR2/KDR kinase, VEGFR1/FLT-1 kinase, and VEGFR3/FLT-4 kinase with IC50 of 18 nM, 12 nM, and 17 nM. |
402857-58-3 |
DC7347 |
Cephalosporin C Na salt
Featured
Cephalosporin C Na salt is used to study the effect of transpeptidase expression, binding, and inhibition on bacterial cell wall mucopeptide synthesis. |
74970-31-3 |
DC7346 |
Cephalosporin C zinc salt
Featured
Cephalosporin C zinc salt is used to study the effect of transpeptidase expression, binding, and inhibition on bacterial cell wall mucopeptide synthesis. |
59143-60-1 |
DC9649 |
Cephalotaxlen
Featured
Cephalotaxine is an antiviral as well as antitumor agent. |
24316-19-6 |
DC10226 |
Cefradine
Cephradine is a semi-synthetic cephalosporin antibiotic. |
38821-53-3 |
DC9765 |
CERC-501(LY-2456302,Aticaprant)
Featured
CERC-501(LY-2456302) is a potent, selective antagonist of the kappa opioid receptor (KOR) (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ-opioid receptor (MOR) and δ-opioid receptor (DOR), respectively. |
1174130-61-0 |
DC7814 |
Cerdulatinib(PRT-062070; PRT2070)
Featured
Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor. |
1198300-79-6 |
DC9154 |
Cetirizine 2HCl
Cetirizine 2Hcl, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria. |
83881-52-1 |
DC9500 |
Cevimeline (hydrochloride hemihydrate)
Featured
Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. |
153504-70-2 |
DC7899 |
Cevipabulin(TTI 237)
Cevipabulin, also known as TTI-237, an antimicrotubule agent, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity. |
849550-05-6 |
DC10440 |
Namodenoson (CF-102)
Featured
CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist; |
163042-96-4 |
DC22052 |
CFI02
CFI02 (CFI-02) is a specific inhibitor of human cytomegalovirus (HCMV) glycoprotein B-mediated fusion with IC50 of 40 nM against laboratory adapted HCMV strain AD169. |
273735-28-7 |
DC10069 |
CFI-400437
Featured
CFI-400437 is potent against PLK4 (IC50 = 0.6 nM) and selective against other members of the PLK family (>10 uM). |
1247000-76-5 |
DC23338 |
CFI-401980
CFI-401980 is a potent, selective, novel class TTK (Tyrosine Threonine Kinase) inhibitor with Ki of 0.8 nM, HCT116 GI50 of 13 nM. |
1610676-27-1 |
DC9340 |
CFM-2
CFM-2 is a selective non-competitive AMPAR antagonist. |
178616-26-7 |
DC11133 |
CFM-4.16
CFM-4.16 is a CARP-1 functional mimetic (CFM) compound bind with CARP-1, stimulates CARP-1 expression and apoptosis. |
1426415-28-2 |
DC22809 |
c-FMS-IN-8
Featured
c-FMS-IN-8 is a potent, selective c-FMS kinase inhibitor with IC50 of 0.8 nM, shows activity in collagen-induced model of arthritis in mice.. |
885704-21-2 |
DC7039 |
CFTR Inhibitor II
Featured
CFTR Inhibitor II is a cell-permeable glycinyl hydrazone compound that acts as a potent, selective and reversible open-channel blocker of CFTR with intermediate speed (< 1 min; 95% inhibition at 50 µM; Ki = 4.3 µM in CFTR-expressing FRT cells. |
328541-79-3 |
DC12580 |
CG-806
Featured
CG-806 (CG806, CG'806) is a novel potent, pan-FLT3/BTK multi-kinase inhibitor with impressive inhibition of leukemic cell proliferation with IC50 at sub-nanomolar or low nanomolar levels. |
1370466-81-1 |
DC7380 |
CGI-1746
Featured
CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. |
910232-84-7 |
DC7101 |
CGK733
Featured
CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM. |
905973-89-9 |
DC10843 |
CGP 52432
Featured
CGP 52432 is a potent, selective GABAB receptor antagonist (IC50 = 85 nM). |
139667-74-6 |
DC7381 |
CGP-57380
Featured
CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 (IC50 = 2.2 μM) with no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases. |
522629-08-9 |
DC10722 |
CGP-71683A
Featured
CGP 71683A is a potent and highly selective non-peptide antagonist of the NPY Y(5) receptor in the study of obesity. |
192322-50-2 |
DC9849 |
CGP37849
CGP37849 is a potent, selective and competitive NMDA receptor antagonist (Ki = 35 nM). Anticonvulsive following oral administration in vivo. |
127910-31-0 |
DC23919 |
CGP-42112
Featured
CGP-42112 (CGP42112A) is a highly potent, selective Angiotensin-II subtype 2 receptor(AT2 receptor) agonist with Ki of 0.24 nM. |
127060-75-7 |
DC23830 |
CGP-53353
CGP-53353 (DAPH-7) is a selective inhibitor of PKCβII with IC50 of 0.41 uM, shows weak activity on PKCβI with IC50 of 3.8 uM. |
145915-60-2 |
DC20887 |
CGP-74514A hydrochloride
CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM. |
481724-82-7 |
DC8471 |
CGS 21680 hydrochloride
Featured
CGS 21680 hydrochloride is an A2A adenosine receptor agonist (Ki = 27 nM). |
124431-80-7 |
DC24112 |
CGS 21680
CGS 21680 is a specific adenosine A2A subtype receptor agonist with Ki of 27 nM. |
120225-54-9 |
DC21331 |
CGS 27023A
CGS 27023A (MMI 270) is a potent, orally active MMP inhibitor with Ki of 8-43 nM for MMP1/2/3/9. |
169799-04-6 |
DC7939 |
CH-223191
Featured
CH-223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. |
301326-22-7 |
DC10974 |
Ch-319
Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer. |
|
DC7102 |
CH5132799
Featured
CH5132799 selectively inhibits class I PI3Ks, such as PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ with IC50 values of 0.014, 0.12, 0.50, and 0.36 uM, respectively; shows less inhibition of class II PI3Ks, class III PI3ks, and mTOR. |
1007207-67-1 |
DC8418 |
CH5183284 (Debio-1347)
Featured
CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1. |
1265229-25-1 |
DC7383 |
CH5424802(Alectinib)
Featured
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
1256580-46-7 |
DC8728 |
CH5424802(Alectinib HCl)
Featured
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
1256589-74-8 |
DC22054 |
CH5447240
Featured
CH5447240 is a novel potent, selective, orally active hPTHR1 agonist with EC20 of 3.0 nM and EC50 of 12 nM. |
1253919-92-4 |
DC12415 |
CH7057288
Featured
CH7057288 (CH-7057288) is a novel potent and selective pan-TRK inhibitor with IC50 of 1.1/7.8/5.1 nM for TRKA/TRKB/TRKC, respectively. |
2095616-82-1 |
DC20337 |
Chaetocin
Chaetocin is a potent, specific, SAM-competitive inhibitor of histone H3K9 methyltransferase (HMT) SU(VAR)3-9 with IC50 of 0.6 uM, no actiivty against H4 Lys20-specific HMT PRSET7 and SET7/9. |
28097-03-2 |
DC5135 |
Chaetominine
Chaetominine , an alkaloidal metabolite with a new framework, was characterized from the solid-substrate culture of Chaetomium sp. |
918659-56-0 |
DC12545 |
CHDI-390576
Featured
CHDI-390576 (CHDI390576) is a potent, cell permeable and CNS penetrant class IIa HDAC inhibitor with IC50 of 54/60/31/50 nM for HDAC4/5/7/9, respectively. |
1629729-98-1 |
DC23101 |
Chelerythrine chloride
Featured
Chelerythrine is a potent, cell permeable inhibitor of protein kinase C (IC50 = 660 nM) that does not inhibit tyrosine protein kinases, cAMP-dependent protein kinase, or calcium/calmodulin-dependent protein kinase. |
3895-92-9 |